Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Efgartigimod alfa by Argenx for Bullous Pemphigoid: Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase...
Empasiprubart by Argenx for Multifocal Motor Neuropathy: Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Multifocal Motor Neuropathy. According to GlobalData, Phase...
(Efgartigimod alfa + hyaluronidase (human recombinant)) by Argenx for Graves' Ophthalmopathy: Likelihood of Approval
(Efgartigimod alfa + hyaluronidase (human recombinant)) is under clinical development by Argenx and currently in Phase III for Graves' Ophthalmopathy....
Empasiprubart by Argenx for Delayed Graft Function (DGF): Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Delayed Graft Function (DGF). According to GlobalData,...
Efgartigimod alfa by Argenx for Immune Mediated Necrotizing Myopathy (IMNM): Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Immune Mediated Necrotizing Myopathy (IMNM). According...
Efgartigimod alfa by Argenx for Tachycardia (Tachyarrhythmias): Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase II for Tachycardia (Tachyarrhythmias). According to GlobalData, Phase...
Efgartigimod alfa by Argenx for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Idiopathic Inflammatory Myopathy (IIM). According to...
Efgartigimod alfa by Argenx for Primary Sjogren's Syndrome: Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase II for Primary Sjogren's Syndrome. According to GlobalData,...
Empasiprubart by Argenx for Dermatomyositis: Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs...
Efgartigimod alfa by Argenx for Antibody-Mediated Rejection (AMR): Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase I for Antibody-Mediated Rejection (AMR). According to GlobalData,...
Efgartigimod alfa by Argenx for Dermatomyositis: Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Dermatomyositis. According to GlobalData, Phase III...
Efgartigimod alfa by Argenx for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....
Efgartigimod alfa by Argenx for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Pre-Registration for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to...
Efgartigimod alfa by Argenx for Primary Sjogren's Syndrome: Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase II for Primary Sjogren's Syndrome. According to GlobalData,...
Empasiprubart by Argenx for Dermatomyositis: Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase I for Dermatomyositis. According to GlobalData, Phase I drugs...
Efgartigimod alfa by Argenx for Antibody-Mediated Rejection (AMR): Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase I for Antibody-Mediated Rejection (AMR). According to GlobalData,...
Efgartigimod alfa by Argenx for Dermatomyositis: Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Dermatomyositis. According to GlobalData, Phase III...
Efgartigimod alfa by Argenx for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....
Efgartigimod alfa by Argenx for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
Efgartigimod alfa is under clinical development by Argenx and currently in Pre-Registration for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to...
Risk adjusted net present value: What is the current valuation of Argenx's Empasiprubart?
Empasiprubart is a monoclonal antibody commercialized by Argenx, with a leading Phase II program in Multifocal Motor Neuropathy. According to...